Covid-19

#Clinical trial #Covid-19 #Moderna

Positive data from Moderna study of Covid-19 vaccine in children 

Moderna has announced positive interim data from its Phase II/III study (KidCOVE) of mRNA-1273, the company’s vaccine candidate against Covid-19, in children six to 12 years of age.   This interim analysis showed a robust neutralising antibody response after two doses of mRNA-1273 at the 50µg dose level with a favourable… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

New consortium to boost Covid-19 vaccine production in South Africa 

The Medicines Patent Pool (MPP), the World Health Organization (WHO), Afrigen Biologics, the Biologicals and Vaccines Institute of Southern Africa (Biovac), the South African Medical Research Council (SAMRC), and Africa Centres for Disease Control and Prevention (Africa CDC) have signed a letter of intent to address the global… Read More

#News

#Awards #Covid-19

Certara’s Covid-19 vaccine model wins R&D 100 Award

Certara’s Simcyp Covid-19 vaccine model has won an R&D 100 Award, which recognises the top 100 “R&D pioneers and their revolutionary ideas in science and technology” during the year.    The model has been used by major pharmaceutical companies and allows researchers to study how a vaccine is handled by the human body… Read More

#News

#Covid-19 #EMA #FDA #Immunology / Virology & Vaccines #Pfizer

Pfizer and BioNTech submit data for the vaccination of children 5 to 12 years 

Pfizer and BioNTech have submitted data supporting the vaccination of children 5 to 12 years of age with Comirnaty (Covid-19 mRNA vaccine) to the European Medicines Agency (EMA) for a variation of the Conditional Marketing Authorization (CMA) in the European Union (EU). According to The New York Times, federal regulators evaluated the… Read More

#News

#Biotechnology #Clinical trials #Covid-19 #Drug discovery #Pharmaceuticals #Pharmacology

Apeiron Biologics begins Covid-19 trial for inhaled drug candidate

Apeiron Biologics has begun a Phase I trial for inhalation of APN01, a recombinant human angiotensin-converting enzyme 2 developed to treat Covid-19 patients by neutralising SARS-CoV-2 in the lungs and mitigating lung damage caused by the infection.   The double-blind, placebo-controlled, dose-escalation study plans to enroll about 40 healthy volunteers in Austria… Read More

#News

#Covid-19 #ELRIG #Life sciences

Reflections from Steve Rees, OBE recipient

Acknowledging a successful career, a significant contribution to drug discovery and the ELRIG community, as well as a recent OBE, Steve Rees, VP Discovery Biology, R&D, AstraZeneca, discusses pivotal moments in his career, the work he coordinated around the Cambridge Covid-19 Test Centre, and his eagerness to re-connect with friends and colleagues… Read More

#Covid-19 #Editor's Choice #Exclusive Content #News

#Covid-19 #Drug discovery #ELRIG

The Covid-19 testing journey and beyond 

The Covid-19 pandemic has forced the drug discovery industry to re-imagine how it operates, as well as the roles within it. Rob Howes, Director of AstraZeneca's Cambridge Covid-19 Testing Centre, believes ELRIG’s Drug Discovery 2021 will be an opportunity for the industry to re-connect as we return to in-person events and scientists return… Read More

#Covid-19 #Editor's Choice #Exclusive Content #News #Opinion

#Alzheimer's #Biotechnology #Covid-19 #Research

How has the pandemic impacted Alzheimer’s research? 

Sara Imarisio, Head of Strategic Initiatives at Alzheimer’s Research UK, reveals what dementia research could deliver and how Alzheimer’s research can help us re-imagine a future in which lives are saved.  Alzheimer’s and other forms of dementia have been impacted by Covid-19. With many labs forced to close during lockdown, and social… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#AI #Covid-19 #Drug discovery #Pharmaceuticals

Understanding impact of pandemic-driven AI on drug discovery

In 18 months, vaccine research advanced AI in medicine by five to seven years. That’s cause for optimism — and investment — in the digital transformation of clinical development. Jeff Elton, CEO of ConcertAI, who has extensive experience in this sector, shares his insight with DDW. There has been a… Read More

#Business & Investment #Covid-19 #Editor's Choice #Exclusive Content #News #Opinion

#Antibodies #Covid-19 #Drug development #Drug discovery #Preclinical development #Therapeutics

Highlights of Carterra’s Bamlanivimab story

A recent sponsored DDW Sitting Down With podcast covered the bamlanivimab story and how this therapeutic went from lab to clinic in eight months during the pandemic. It is available to listen to here. Lu Rahman selects some of the highlights of this chat with Bryan Jones, Senior Research Fellow, BioTechnology Discovery Research, Eli Lilly and Company and Dan Bedinger, Application… Read More

#Covid-19 #Exclusive Content #News

#Alzheimer's #Cancer research #Covid-19

This week in drug discovery (4-8 October) 

News round-up by DDW’s Megan Thomas for 4-8 October  For this week’s drug discovery round up, DDW’s Megan Thomas focuses on stories that provide answers to previously unanswered questions, or news that enables researchers and scientists to find those answers quickly.  1. Novel therapy could… Read More

#News #Trending News

#Covid-19 #Drug development #Pharmaceuticals #R&D

Pharmaceutical industry warned not to undo pandemic advances 

Dr Steve Arlington, President of The Pistoia Alliance, has called on the pharmaceutical industry to continue building on the advances in collaboration it has built over the past two years. Digital transformation has accelerated rapidly during the pandemic, which in turn has greatly improved remote patient monitoring, rapid online… Read More

#News

#AstraZeneca #Covid-19 #Drug development #Drug discovery #Events #Immunology / Virology & Vaccines

Race against the virus: Dame Sarah Gilbert discusses her virology journey 

In late December 2019, a cluster of unusual pneumonia cases – now known to be the first human cases of Covid-19 – were reported in Wuhan, China. Due to quick action from Dame Sarah Gilbert and her team, work on the response to the new virus began. Members of… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines #Research

Why some people have stronger natural defences against SARS-COV-2 

A team of scientists at the MRC University of Glasgow Centre for Virus Research has revealed key research into the natural human antiviral defences against SARS-CoV-2, the virus that causes Covid-19.   In the study, the scientists reveal that some people have a version of a gene,… Read More

#News

#Antivirals #Covid-19 #Drug discovery

Covid-19 antiviral pill cuts hospitalisation and deaths in half

If authorised, molnupiravir could be the first oral antiviral medicine for Covid-19. Merck (known as MSD outside the United States and Canada) and Ridgeback Biotherapeutics have announced that molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalisation or death at a planned interim analysis of the Phase… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Bioscience #Covid-19 #High throughput screening

Twist Bioscience antibody shows potent binding to SARS-CoV-2 strains 

Twist Bioscience has reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094) demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of Covid-19.   The Coronavirus Immunotherapy… Read More

#News